Addex Therapeutics (ADXN) Competitors $9.36 +0.12 (+1.30%) As of 02:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADXN vs. PLUR, MRSN, MURA, SNTI, PYRGF, RANI, OKUR, JATT, BCAB, and ITRMShould you be buying Addex Therapeutics stock or one of its competitors? The main competitors of Addex Therapeutics include Pluri (PLUR), Mersana Therapeutics (MRSN), Mural Oncology (MURA), Senti Biosciences (SNTI), PyroGenesis Canada (PYRGF), Rani Therapeutics (RANI), OnKure Therapeutics (OKUR), JATT Acquisition (JATT), BioAtla (BCAB), and Iterum Therapeutics (ITRM). These companies are all part of the "pharmaceutical products" industry. Addex Therapeutics vs. Its Competitors Pluri Mersana Therapeutics Mural Oncology Senti Biosciences PyroGenesis Canada Rani Therapeutics OnKure Therapeutics JATT Acquisition BioAtla Iterum Therapeutics Pluri (NASDAQ:PLUR) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment. Do analysts recommend PLUR or ADXN? Pluri presently has a consensus target price of $12.00, indicating a potential upside of 166.37%. Addex Therapeutics has a consensus target price of $30.00, indicating a potential upside of 220.51%. Given Addex Therapeutics' higher probable upside, analysts clearly believe Addex Therapeutics is more favorable than Pluri.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Addex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals hold more shares of PLUR or ADXN? 16.6% of Pluri shares are held by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are held by institutional investors. 25.9% of Pluri shares are held by company insiders. Comparatively, 15.0% of Addex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk & volatility, PLUR or ADXN? Pluri has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Addex Therapeutics has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Does the media prefer PLUR or ADXN? In the previous week, Addex Therapeutics had 1 more articles in the media than Pluri. MarketBeat recorded 2 mentions for Addex Therapeutics and 1 mentions for Pluri. Pluri's average media sentiment score of 1.91 beat Addex Therapeutics' score of 0.95 indicating that Pluri is being referred to more favorably in the media. Company Overall Sentiment Pluri Very Positive Addex Therapeutics Positive Which has stronger earnings and valuation, PLUR or ADXN? Addex Therapeutics has lower revenue, but higher earnings than Pluri. Addex Therapeutics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPluri$1.34M27.43-$22.58M-$5.17-0.87Addex Therapeutics$170.62K58.15$8.02M-$0.34-27.53 Is PLUR or ADXN more profitable? Addex Therapeutics has a net margin of 3,584.49% compared to Pluri's net margin of -1,701.19%. Addex Therapeutics' return on equity of -54.27% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets Pluri-1,701.19% -4,191.91% -88.27% Addex Therapeutics 3,584.49%-54.27%-49.15% SummaryAddex Therapeutics beats Pluri on 9 of the 14 factors compared between the two stocks. Get Addex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXN vs. The Competition Export to ExcelMetricAddex TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.93M$2.51B$5.65B$10.26BDividend YieldN/A56.32%5.68%4.61%P/E Ratio-27.5423.2775.7026.05Price / Sales58.15571.43514.05168.79Price / CashN/A174.1537.5661.52Price / Book0.905.1512.876.29Net Income$8.02M$32.95M$3.29B$270.94M7 Day Performance-4.25%0.17%-0.33%-0.30%1 Month Performance12.24%5.12%3.77%6.20%1 Year Performance-1.16%1.29%68.18%28.32% Addex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXNAddex Therapeutics2.2913 of 5 stars$9.36+1.3%$30.00+220.5%-8.4%$9.93M$170.62K-27.5430Upcoming EarningsPLURPluri3.0575 of 5 stars$4.69-0.5%$12.00+156.1%-21.4%$38.23M$1.34M-0.91150Negative NewsMRSNMersana Therapeutics3.8108 of 5 stars$7.31-0.5%$56.60+674.3%-84.6%$36.48M$40.50M-0.50150Positive NewsMURAMural Oncology2.1672 of 5 stars$2.09+0.7%$12.00+475.5%-34.7%$36.13MN/A-0.24119SNTISenti Biosciences2.5972 of 5 stars$1.38-0.7%$8.50+515.9%-51.9%$36.10M$2.56M-0.154PYRGFPyroGenesis CanadaN/A$0.19-0.9%N/A-72.3%$35.86M$9.14M-3.1990RANIRani Therapeutics3.3445 of 5 stars$0.48-2.7%$7.33+1,418.3%-77.7%$34.71M$1.03M-0.53110Positive NewsOKUROnKure Therapeutics2.8125 of 5 stars$2.55-2.3%$32.33+1,168.0%N/A$34.50MN/A-0.53N/AGap UpJATTJATT AcquisitionN/A$1.99-2.9%N/A-52.6%$34.33MN/A0.003High Trading VolumeBCABBioAtla1.1914 of 5 stars$0.58-8.1%N/A-64.1%$33.76M$11M-0.5260Positive NewsITRMIterum Therapeutics2.7622 of 5 stars$0.71+4.4%$9.00+1,167.6%-29.7%$33.49MN/A-0.8410Gap Up Related Companies and Tools Related Companies Pluri Alternatives Mersana Therapeutics Alternatives Mural Oncology Alternatives Senti Biosciences Alternatives PyroGenesis Canada Alternatives Rani Therapeutics Alternatives OnKure Therapeutics Alternatives JATT Acquisition Alternatives BioAtla Alternatives Iterum Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADXN) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Addex Therapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Addex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADXN Stock Alerts